N-methyl-D-aspartate receptor subunit 1 (GluN1) glycine binding site (GluN1 glycine site)

The NMDA receptor GluN1 glycine co-agonist site is a critical regulatory locus on the GluN1 subunit of the N-methyl-D-aspartate (NMDA) receptor, a ligand-gated ion channel essential for excitatory neurotransmission in the central nervous system (Paoletti et al., 2013). Unlike most neurotransmitter receptors, the NMDA receptor requires the simultaneous binding of two distinct agonists for activation: glutamate at the GluN2 subunit and glycine (or D-serine) at the GluN1 subunit (Kleckner and Dingledine, 1988). This site is a major therapeutic target for neuropsychiatric and neurodegenerative disorders, as NMDA receptor hypofunction is implicated in the pathophysiology of schizophrenia and cognitive impairment (Balu, 2016). Pharmacological modulation of this site using agonists or partial agonists, such as D-cycloserine or rapastinel, aims to enhance synaptic plasticity and improve cognitive function (Moskal et al., 2014). Conversely, antagonists have been explored for neuroprotection in conditions like stroke to prevent glutamate-mediated excitotoxicity, although clinical success has been limited (NIH). The site's unique requirement for co-activation provides a sophisticated mechanism for fine-tuning neuronal excitability and synaptic strength (Paoletti et al., 2013).

Other names

NR1 glycine siteGluN1 co-agonist siteStrychnine-insensitive glycine binding siteNMDA receptor co-agonist siteGlycine B site

The GluN1 glycine site acts as an obligatory co-agonist site; its occupancy by glycine or D-serine is required alongside glutamate binding to the GluN2 subunit for the NMDA receptor's ion channel to open (Kleckner and Dingledine, 1988). Drugs targeting this site modulate receptor activity by acting as full agonists, partial agonists, or competitive antagonists, thereby influencing excitatory neurotransmission and synaptic plasticity (Paoletti et al., 2013).